Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artra GroupTSE:6029 -1.01%61 3-Year ROIIC % is -42.35 as of Dec. 2025. GuruFocus rates TSE:6029 with a GF Score™ of 61/100 and a GF Value™ of 円139.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Artra Group ranks worse than 84.49% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Artra Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -42.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Artra Group's 3-Year ROIIC % or its related term are showing as below:
TSE:6029's 3-Year ROIIC % is ranked worse than 84.49% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.48
vs TSE:6029: -42.35
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Artra Group 3-Year ROIIC % Related Terms
Artra Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Artra Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6029 vs HCA, THC, DVA: 3-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, Artra Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artra Group 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Artra Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Artra Group's 3-Year ROIIC % falls into.
Artra Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 140.813 (Dec. 2025) - 0.2214016 (Dec. 2022) )
/
( 2599.124 (Dec. 2025) - 2931.069 (Dec. 2022) )
=
140.5915984
/
-331.945
=
-42.35%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Artra Group (TSE:6029) has a 3-Year ROIIC % of -42.35 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Artra Group and its competitors. According to the industry distribution chart, Artra Group ranks #523 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 84.5%.
Is Artra Group's 3-Year ROIIC % too high?
Artra Group's current 3-Year ROIIC % is -42.35. Based on the distribution chart, Artra Group ranks #523 out of 619 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Artra Group has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Artra Group's 3-Year ROIIC % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Artra Group ranks #523 out of 619 companies for 3-Year ROIIC %. This places Artra Group in the lower half of its industry. The industry median 3-Year ROIIC % is 3.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.48, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Artra Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artra Group's current 3-Year ROIIC % is -42.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artra Group stock overvalued right now?
Based on GuruFocus' analysis, Artra Group (TSE:6029) is currently considered Significantly Overvalued. The stock's GF Value™ is 円139.87, compared to a current price of 円196.00 — trading 40.1% above its estimated fair value. The current 3-Year ROIIC % is -42.35. Artra Group's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Artra Group (TSE:6029), the current 3-Year ROIIC % is -42.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artra Group (TSE:6029) Overvalued in 2026?
Based on GuruFocus' analysis, Artra Group stock appears to be overvalued.
The current stock price of 円196.00 is trading 40.1% above its estimated GF Value™ of 円139.87.
GuruFocus considers Artra Group to be Significantly Overvalued.
Key valuation signals for TSE:6029:
3-Year ROIIC %: -42.35
GF Value™: 円139.87 vs. price of 円196.00 (40.1% above fair value)
No single metric tells the full story. See the TSE:6029 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artra Group Corp is engaged in the healthcare support business, providing services that assist the operation and management of clinics and related facilities. The group has two reportable segments: Acupuncture & Orthopedic Clinic Support and Toy Sales Business. The Acupuncture and Orthopedic Clinic Support segment is involved in supporting acupuncture and orthopedic clinics through services such as bone setting chains, provision of equipment and consumables, Attra billing services, HONEY-STYLE, and nursing care support. The Toy Sales segment focuses on the sale of toys, stationery, and other related products.
61GF Score
Get the complete analysis for TSE:6029
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6029 has been successfully added to your 
